Press Releases

Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzymes as many as possible. Last week, the product manager of Creative Enzymes announced the launch of neuraminidase, which is expected to further develop a new universal influenza vaccine.

Neuraminidase is a drug target to prevent the spread of influenza infection. As early as the 1940s, American scientist George Hirst discovered a substance that destroys receptors on the surface of red blood cells in a sample of influenza virus mixed with red blood cells (red blood cells). Since then, British biochemist Alfred Gottschalk discovered that these receptor-damaging enzymes are neuraminidase.

Influenza endangers human health for a long time, and seasonal flu causes repeated harm to society and the economy. Every year, about 3 to 5 million people worldwide suffer from severe pneumonia due to seasonal influenza, and the death toll is as high as 250,000 to 500,000. Vaccine is one of the main measures to prevent and control influenza. At present, seasonal influenza vaccine mainly targets hemagglutinin, the membrane protein on the surface of influenza virus. However, according to data from the US Centers for Disease Control and Prevention, the average protection rate of influenza vaccines in North America in the past 10 years is only 40%, and there is still a lot of room for improvement. Therefore, scientists have been trying to find new ways to improve the effectiveness of vaccines.

“The study of hemagglutinin is the mainstream of influenza vaccine research and development. However, multiple evidences indicate that neuraminidase, another membrane protein of influenza virus, plays a pivotal role in the life cycle of the virus. Therefore, the main research currently being conducted by scientists is to understand the humoral immune response of neuraminidase in the human body, and to provide a new and powerful scientific basis for the research and development of influenza vaccines, so as to more effectively prevent and treat influenza viruses.” Said the Chief Scientist of Creative Enzymes. 

“Creative Enzymes has recently launched neuraminidase, this products will have better market prospects based on large demands and their specific features.” He added.

Creative Enzymes has a professional research and development team of enzyme products and services. Team members have a high level of expertise and rich experience. Therefore, the company can provide customers with comprehensive, professional, and one-stop solutions.

About Creative Enzymes

Creative Enzymes is a remarkable supplier and manufacturer in Enzymology field. Equipped with advanced technique platform, Creative Enzymes is able to offer high-quality and professional services for customers. Its products and services are widely used in academic and pharmaceutical industries.